Your browser doesn't support javascript.
loading
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu, Fengcai; Zhuang, Chunlan; Chu, Kai; Zhang, Liang; Zhao, Hui; Huang, Shoujie; Su, Yingying; Lin, Hongyan; Yang, Changlin; Jiang, Hanmin; Zang, Xia; Liu, Donglin; Pan, Hongxing; Hu, Yuemei; Liu, Xiaohui; Chen, Qi; Song, Qiaoqiao; Quan, Jiali; Huang, Zehong; Zhong, Guohua; Chen, Junyu; Han, Jinle; Sun, Hong; Cui, Lunbiao; Li, Jingxin; Chen, Yixin; Zhang, Tianying; Ye, Xiangzhong; Li, Changgui; Wu, Ting; Zhang, Jun; Xia, Ning-Shao.
Afiliación
  • Zhu F; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China. Electronic address: jszfc@jscdc.cn.
  • Zhuang C; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Chu K; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China.
  • Zhang L; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhao H; National Institute for Food and Drug Control, Beijing, China.
  • Huang S; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Su Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Lin H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Yang C; Dongtai Centre for Disease Control and Prevention, Yancheng, Jiangsu, China.
  • Jiang H; Dongtai Centre for Disease Control and Prevention, Yancheng, Jiangsu, China.
  • Zang X; Dongtai Centre for Disease Control and Prevention, Yancheng, Jiangsu, China.
  • Liu D; Dongtai Centre for Disease Control and Prevention, Yancheng, Jiangsu, China.
  • Pan H; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China.
  • Hu Y; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China.
  • Liu X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Chen Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Song Q; Beijing Wantai Biological Pharmacy Enterprise, Beijing, China.
  • Quan J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Huang Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhong G; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Chen J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Han J; Beijing Wantai Biological Pharmacy Enterprise, Beijing, China.
  • Sun H; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China.
  • Cui L; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China.
  • Li J; Jiangsu Provincial Centre for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, Jiangsu, China.
  • Chen Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhang T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Ye X; Beijing Wantai Biological Pharmacy Enterprise, Beijing, China.
  • Li C; National Institute for Food and Drug Control, Beijing, China.
  • Wu T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Xia NS; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China; Research Unit of Frontie
Lancet Respir Med ; 10(8): 749-760, 2022 08.
Article en En | MEDLINE | ID: mdl-35644168
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Orthomyxoviridae / Vacunas Virales / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: Lancet Respir Med Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Orthomyxoviridae / Vacunas Virales / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: Lancet Respir Med Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido